Mustang Bio, Inc.

As of June 13, 2025, Mustang Bio, Inc. is in a bearish trend with moderate strength, driven by bearish daily moving averages, a bearish monthly RSI, and underperformance against the S&P 500, despite some mildly bullish signals from the weekly MACD and KST.

As of March 2022, the management team of Mustang Bio, Inc. includes Executive Chairman Michael Weiss, President and CEO Dr. Manuel Litchman, and Directors Dr. Lindsay Rosenwald, Adam Chill, Neil Herskowitz, and Dr. Michael Zelefsky. They oversee the company's strategic direction and operations.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on cell and gene therapy for hematologic cancers, solid tumors, and rare genetic diseases. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $4.47 million and has no recent net sales or profits.

As of Jun 18, Mustang Bio, Inc. has a market capitalization of 4.47 million, with net sales of 0.00 million and a net profit of -10.71 million over the latest four quarters. The balance sheet shows shareholder's funds of -3.87 million and total assets of 9.31 million.